Gilead’s Kite is linking with Sangamo Therapeutics in a collaboration that aims to develop next-generation engineered cell therapies for the treatment of cancer.
News
NHS making 237m medication errors a year
NHS medication errors could be playing a role in up to 22,000 patients deaths every year, suggest findings from a new study.
Finalists soon to be revealed!
Clinical researchers the world over have submitted essays for this year’s competition and yesterday, the authors and finalists were identified at a special meeting of the executive steering group
NICE sticks with ‘no’ for earlier use of Halaven
Cost regulators for NHS treatments in England and Wales are sticking with their position that Eisai’s Halaven should not be funded by the NHS as a second-line of attack against a certain form of breast cancer.
Major study backs efficacy of antidepressants
A large-scale review of the most common antidepressants has found them all to be superior to placebo in treating major depression, potentially laying to rest questions over their effectiveness.
GW’s cannabinoid fails in focal seizures trial
A mid-stage trial assessing an experimental cannabinoid being developed by GW Pharma for adults with focal seizures has failed to hit key targets.
Arix ties with Ipsen
London, UK-based Arix Bioscience has entered into a strategic agreement with French drugmaker Ipsen to develop and commercialise innovative therapies.
NHS books £1.2bn deficit and 100,000 empty posts
Alarm bells over the state of the NHS are ringing again after the latest quarterly report on its performance show “intolerable pressures” and a deeper swing into the red.
Merck buys Australia’s Viralytics
Merck & Co is broadening its immuno-oncology offering through the purchase of Australian group Viralytics in a deal worth $394 million.
NHS England promotes joint working with local authorities
England’s top A&E doctor is calling for a closer working relationship between the NHS and local authorities to help improve the health of local communities.
Aimmune’s peanut allergy drug hits PhIII targets
A Phase III trial assessing Aimmune Therapeutics’ experimental peanut allergy drug AR101 has hit its primary targets.
AbbVie, Voyager to develop single gene therapy for Alzheimer’s
AbbVie and Voyager Therapeutics are joining forces to develop a new therapy for Alzheimer’s disease and other neurodegenerative conditions.
NICE nod for Gilead’s pan-genotypic hepatitis C therapy
Gilead’s pan-genotypic treatment for hepatitis C Vosevi has won the National Institute for Health and Care Excellence’s seal of approval for use on the NHS.
New prescriptions of Gideon Richter’s Esyma on hold
Doctors are not to prescribe Gedeon Richter’s Esmya for uterine fibroids in the UK while European regulators carry out a safety review of the drug.
Shire, Microsoft and EURODIS form rare diseases alliance
Shire has teamed up with Microsoft and EURORDIS-Rare Diseases Europe in a strategic alliance aiming to tackle the diagnostic challenge for patients living with a rare disease.
